Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Brief Report titled “Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non–Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial,”1 published online August 30, 2018, there was an error in Figure 2. The text and the overall survival data were correct, but the Kaplan-Meier curves and median values were incorrect. This article was corrected online.
Error in Figure 2. JAMA Oncol. 2018;4(12):1792. doi:10.1001/jamaoncol.2018.6227
Artificial Intelligence Resource Center